PRAME expression in hairy cell leukemia

Leukemia Research

Volumn 32, Issue 9, 2008, Pages 1400-1406

  Arons, Evgeny ^a   Suntum, Tara ^a   Margulies, Inger ^a   Yuan, Constance ^a   Stetler Stevenson, Maryalice ^a   Kreitman, Robert J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chronic lymphocytic leukemia; Hairy cell leukemia; Minimal residual disease; PRAME; Real time PCR; TaqMan

Indexed keywords

ANTINEOPLASTIC AGENT; BL 22; ONCOPROTEIN; PROTEIN PRAME;

ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, NEOPLASM; CASE-CONTROL STUDIES; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, HAIRY CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 43049172283     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.12.010     Document Type: Article

References (41)

1. Ikeda H., Lethe B., Lehmann F., van Baren N., Baurain J.F., de Smet C., et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6 (1997) 199-208
2. Kessler J.H., Beekman N.J., Bres-Vloemans S.A., Verdijk P., van Veelen P.A., Kloosterman-Joosten A.M., et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 193 (2001) 73-88
3. Partheen K., Levan K., Osterberg L., and Horvath G. Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer 42 (2006) 2846-2854
4. Doolan P., Clynes M., Kennedy S., Mehta J.P., Crown J., and O'Driscoll L. Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat (2007)
5. Boon K., Edwards J.B., Siu I.M., Olschner D., Eberhart C.G., Marra M.A., et al. Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene 22 (2003) 7687-7694
6. Segal N.H., Blachere N.E., Guevara-Patino J.A., Gallardo H.F., Shiu H.Y., Viale A., et al. Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. Cancer Immun 5 (2005) 2
7. Figueiredo D.L., Mamede R.C., Proto-Siqueira R., Neder L., Silva Jr. W.A., and Zago M.A. Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head Neck 28 (2006) 614-619
8. Oberthuer A., Hero B., Spitz R., Berthold F., and Fischer M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 10 (2004) 4307-4313
9. Neumann E., Engelsberg A., Decker J., Storkel S., Jaeger E., Huber C., et al. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?. Cancer Res 58 (1998) 4090-4095
10. Li C.M., Guo M., Borczuk A., Powell C.A., Wei M., Thaker H.M., et al. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 160 (2002) 2181-2190
11. van Baren N., Chambost H., Ferrant A., Michaux L., Ikeda H., Millard I., et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 102 (1998) 1376-1379
12. Proto-Siqueira R., Falcao R.P., de Souza C.A., Ismael S.J., and Zago M.A. The expression of PRAME in chronic lymphoproliferative disorders. Leuk Res 27 (2003) 393-396
13. Paydas S., Tanriverdi K., Yavuz S., Disel U., Baslamisli F., and Burgut R. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol 79 (2005) 257-261
14. Greiner J., Ringhoffer M., Taniguchi M., Li L., Schmitt A., Shiku H., et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 108 (2004) 704-711
15. Steinbach D., Hermann J., Viehmann S., Zintl F., and Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 133 (2002) 118-123
16. Steinbach D., Viehmann S., Zintl F., and Gruhn B. PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet 138 (2002) 89-91
17. Tajeddine N., Millard I., Gailly P., and Gala J.L. Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. Clin Chem Lab Med 44 (2006) 548-555
18. Matsushita M., Ikeda H., Kizaki M., Okamoto S., Ogasawara M., Ikeda Y., et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol 112 (2001) 916-926
19. Radich J.P., Dai H., Mao M., Oehler V., Schelter J., Druker B., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 103 (2006) 2794-2799
20. Roman-Gomez J., Jimenez-Velasco A., Agirre X., Castillejo J.A., Navarro G., Jose-Eneriz E.S., et al. Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk Res (2007)
21. Willenbrock K., Kuppers R., Renne C., Brune V., Eckerle S., Weidmann E., et al. Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma. Haematologica 91 (2006) 596-604
22. Abramenko I.V., Belous N.I., Kriachok I.A., Chumak A.A., Aksenova E.V., Lisovskaia E.V., et al. Expression of PRAME gene in multiple myeloma. Ter Arkh 76 (2004) 77-81
23. Pellat-Deceunynck C., Mellerin M.P., Labarriere N., Jego G., Moreau-Aubry A., Harousseau J.L., et al. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol 30 (2000) 803-809
24. Proto-Siqueira R., Figueiredo-Pontes L.L., Panepucci R.A., Garcia A.B., Rizzatti E.G., Nascimento F.M., et al. PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res 30 (2006) 1333-1339
25. Paydas S., Tanriverdi K., Yavuz S., and Seydaoglu G. PRAME mRNA levels in cases with chronic leukemia: clinical importance and review of the literature. Leuk Res 31 (2007) 365-369
26. Giannopoulos K., Li L., Bojarska-Junak A., Rolinski J., Dmoszynska A., Hus I., et al. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. Int J Oncol 29 (2006) 95-103
27. Epping M.T., Wang L., Edel M.J., Carlee L., Hernandez M., and Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122 (2005) 835-847
28. Tajeddine N., Gala J.L., Louis M., Van Schoor M., Tombal B., and Gailly P. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res 65 (2005) 7348-7355
29. Schenk T., Stengel S., Goellner S., Steinbach D., and Saluz H.P. Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. Genes Chromosomes Cancer 46 (2007) 796-804
30. Spanaki A., Perdikogianni C., Linardakis E., and Kalmanti M. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia. Leuk Res 31 (2007) 639-642
31. Arons E., Sunshine J., Suntum T., and Kreitman R.J. Somatic hypermutation and VH gene usage in hairy cell leukemia. Br J Haematol 133 (2006) 504-512
32. Vanhentenrijk V., Tierens A., Wlodarska I., Verhoef G., and Wolf-Peeters C.D. V(H) gene analysis of hairy cell leukemia reveals a homogeneous mutation status and suggests its marginal zone B-cell origin. Leukemia 18 (2004) 1729-1732
33. Sausville J.E., Salloum R., Sorbara L., Kingma D.W., Raffeld M., Kreitman R.J., et al. Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol 119 (2003) 213-217
34. Kamiguti A.S., Serrander L., Lin K., Harris R.J., Cawley J.C., Allsup D.J., et al. Expression and activity of NOX5 in the circulating malignant B cells of hairy cell leukemia. J Immunol 175 (2005) 8424-8430
35. Goodman G.R., Bethel K.J., and Saven A. Hairy cell leukemia: an update. Curr Opin Hematol 10 (2003) 258-266
36. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods Cell Biol 25 (2001) 402-408
37. Lossos I.S., Czerwinski D.K., Wechser M.A., and Levy R. Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia 17 (2003) 789-795
38. Kreitman R.J., Wilson W.H., Bergeron K., Raggio M., Stetler-Stevenson M., FitzGerald D.J., et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345 (2001) 241-247
39. Kreitman R.J., Squires D.R., Stetler-Stevenson M., Noel P., Fitzgerald D.J., Wilson W.H., et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 23 (2005) 6719-6729
40. Arons E., Margulies I., Sorbara L., Raffeld M., Stetler-Stevenson M., Pastan I., et al. Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction. Clin Cancer Res 12 (2006) 2804-2811
41. Arons E., Suntum T., Sunshine J., Stetler-Stevenson M., and Kreitman R.J. Immunoglobulin light chain repertoire in hairy cell leukemia. Leuk Res 31 (2007) 1239-1244